Patents by Inventor Abebe Akalu
Abebe Akalu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8133471Abstract: The invention describes methods for inhibiting angiogenesis in a tissue by administering an antagonist that specifically binds to a proteolyzed or denatured collagen type-IV with substantially greater affinity than to the native triple helical form of collagen type-IV. Methods utilizing such antagonists for therapeutic treatment of tumor growth, tumor metastasis or of restenosis also are described, as are methods to use such antagonists as diagnostic markers of angiogenesis in normal or diseased tissues both in vivo and ex vivo. The invention further describes methods for treating tumors using said antagonists in combination with radiation therapy and therapies comprising the antagonists and radiation treatment.Type: GrantFiled: December 21, 2009Date of Patent: March 13, 2012Assignee: New York UniversityInventors: Peter C. Brooks, Jennifer Roth, Abebe Akalu
-
Publication number: 20100226852Abstract: The invention describes methods for inhibiting angiogenesis in a tissue by administering an antagonist that specifically binds to a proteolyzed or denatured collagen type-IV with substantially greater affinity than to the native triple helical form of collagen type-IV. Methods utilizing such antagonists for therapeutic treatment of tumor growth, tumor metastasis or of restenosis also are described, as are methods to use such antagonists as diagnostic markers of angiogenesis in normal or diseased tissues both in vivo and ex vivo. The invention further describes methods for treating tumors using said antagonists in combination with radiation therapy and therapies comprising the antagonists and radiation treatment.Type: ApplicationFiled: December 21, 2009Publication date: September 9, 2010Applicant: NEW YORK UNIVERSITYInventors: Peter C. Brooks, Jennifer Roth, Abebe Akalu
-
Patent number: 7662783Abstract: The invention describes methods for inhibiting angiogenesis in a tissue by administering an antagonist that specifically binds to a proteolyzed or denatured collagen type-IV with substantially greater affinity than to the native triple helical form of collagen type-IV. Methods utilizing such antagonists for therapeutic treatment of tumor growth, tumor metastasis or of restenosis also are described, as are methods to use such antagonists as diagnostic markers of angiogenesis in normal or diseased tissues both in vivo and ex vivo. The invention further describes methods for treating tumors using said antagonists in combination with radiation therapy and therapies comprising the antagonists and radiation treatment.Type: GrantFiled: October 14, 2005Date of Patent: February 16, 2010Assignee: New York UniversityInventors: Peter C. Brooks, Jennifer Roth, Abebe Akalu
-
Publication number: 20090226369Abstract: The invention describes methods for inhibiting angiogenesis in a tissue by administering an antagonist that specifically binds to a proteolyzed or denatured laminin with substantially greater affinity than to the native form of laminin. Methods utilizing such antagonists for therapeutic treatment of tumor growth, tumor metastasis or of restenosis also are described, as are methods to use such antagonists as diagnostic markers of angiogenesis in normal or diseased tissues both in vivo and ex vivo.Type: ApplicationFiled: May 12, 2008Publication date: September 10, 2009Applicant: NEW YORK UNIVERSITYInventors: Peter C. Brooks, Abebe Akalu
-
Patent number: 7387998Abstract: The invention describes methods for inhibiting angiogenesis in a tissue by administering an antagonist that specifically binds to a proteolyzed or denatured laminin with substantially greater affinity than to the native form of laminin. Methods utilizing such antagonists for therapeutic treatment of tumor growth, tumor metastasis or of restenosis also are described, as are methods to use such antagonists as diagnostic markers of angiogenesis in normal or diseased tissues both in vivo and ex vivo.Type: GrantFiled: March 9, 2004Date of Patent: June 17, 2008Assignee: New York UniversityInventors: Peter C. Brooks, Abebe Akalu
-
Publication number: 20070259817Abstract: The invention describes methods for inhibiting angiogenesis in a tissue by administering an antagonist that specifically binds to a proteolyzed or denatured collagen type-IV with substantially greater affinity than to the native triple helical form of collagen type-IV. Methods utilizing such antagonists for therapeutic treatment of tumor growth, tumor metastasis or of restenosis also are described, as are methods to use such antagonists as diagnostic markers of angiogenesis in normal or diseased tissues both in vivo and ex vivo. The invention further describes methods for treating tumors using said antagonists in combination with radiation therapy and therapies comprising the the antagonists and radiation treatment.Type: ApplicationFiled: October 14, 2005Publication date: November 8, 2007Inventors: Peter Brooks, Jennifer Roth, Abebe Akalu
-
Publication number: 20060240002Abstract: The invention provides methods for identifying genes and proteins modulated by an antagonist to a cryptic epitope of an ECM component that specifically binds to the ECM component. It additionally provides methods for using the products of the identified genes, or for using the identified proteins, for inhibiting angiogenesis, tumor metastasis, and other tumor developmental processes, including cell migration, cell adhesion, cell proliferation, and tumor growth and for treating angiogenesis-dependent conditions. The present invention also relates to antagonists of cryptic epitopes of ECM components, wherein binding of these antagonists to cryptic epitopes of ECM components results in modulation of the expression of IGFBP-4, TSP-1, Id-1, p27KIP or p21CIP, and methods of using these antagonists for inhibiting angiogenesis, tumor metastasis, and other tumor development processes as well as for treating angiogenesis-dependent conditions.Type: ApplicationFiled: March 9, 2006Publication date: October 26, 2006Inventors: Peter Brooks, Abebe Akalu, Alexandra Cretu, Desiree Policarpio
-
Publication number: 20060216236Abstract: The invention provides methods for identifying genes and proteins modulated by an antagonist of ?v?3 that inhibits binding of ?v?3 to an ECM component. It additionally provides methods for using the products of the identified genes, or for using the identified proteins, for inhibiting angiogenesis, tumor metastasis, and other tumor developmental processes, including cell migration, cell adhesion, cell proliferation, and tumor growth and for treating angiogenesis-dependent conditions. The present invention also relates to antagonists of ?v?3, wherein binding of these antagonists to ?v?3 results in modulation of the expression of IGFBP-4 or TSP-1, and methods of using these antagonists for inhibiting angiogenesis, tumor metastasis, and other tumor development processes as well as for treating angiogenesis-dependent conditions.Type: ApplicationFiled: March 9, 2006Publication date: September 28, 2006Inventors: Peter Brooks, Abebe Akalu, Alexandra Cretu, Desiree Policarpio
-
Publication number: 20060216237Abstract: The invention provides compositions comprising IGFBP-4 and methods for inhibiting angiogenesis and tumor development processes, and for treating angiogenesis-dependent conditions, using an insulin growth factor binding protein, IGFBP-4.Type: ApplicationFiled: March 9, 2006Publication date: September 28, 2006Inventors: Peter Brooks, Abebe Akalu, Alexandra Cretu, Desiree Policarpio
-
Publication number: 20040224896Abstract: The invention describes methods for inhibiting angiogenesis in a tissue by administering an antagonist that specifically binds to a proteolyzed or denatured laminin with substantially greater affinity than to the native form of laminin. Methods utilizing such antagonists for therapeutic treatment of tumor growth, tumor metastasis or of restenosis also are described, as are methods to use such antagonists as diagnostic markers of angiogenesis in normal or diseased tissues both in vivo and ex vivo.Type: ApplicationFiled: March 9, 2004Publication date: November 11, 2004Applicant: NYU Medical CenterInventors: Peter C. Brooks, Abebe Akalu